Woodhoo A, Sahni V, Gilson J, Setzu A, Franklin R J M, Blakemore W F, Mirsky R, Jessen K R
Department of Anatomy and Developmental Biology, University College London, London, UK.
Brain. 2007 Aug;130(Pt 8):2175-85. doi: 10.1093/brain/awm125. Epub 2007 Jun 4.
Cell transplant therapies are currently under active consideration for a number of degenerative diseases. In the immune-mediated demyelinating-neurodegenerative disease multiple sclerosis (MS), only the myelin sheaths of the CNS are lost, while Schwann cell myelin of the PNS remains normal. This, and the finding that Schwann cells can myelinate CNS axons, has focussed interest on Schwann cell transplants to repair myelin in MS. However, the experimental use of these cells for myelin repair in animal models has revealed a number of problems relating to the incompatibility between peripheral glial cells and the CNS glial environment. Here, we have tested whether these difficulties can be avoided by using an earlier stage of the Schwann cell lineage, the Schwann cell precursor (SCP). For direct comparison of these two cell types, we implanted Schwann cells from post-natal rat nerves and SCPs from embryo day 14 (E14) rat nerves into the CNS under various experimental conditions. Examination 1 and 2 months later showed that in the presence of naked CNS axons, both types of cell form myelin that antigenically and ultrastructurally resembles that formed by Schwann cells in peripheral nerves. In terms of every other parameter we studied, however, the cells in these two implants behaved remarkably differently. As expected from previous work, Schwann cell implants survive poorly unless the cells find axons to myelinate, the cells do not migrate significantly from the implantation site, fail to integrate with host oligodendrocytes and astrocytes, and form little myelin when challenged with astrocyte-rich environment in the retina. Following SCP implantation, on the other hand, the cells survive well, migrate through normal CNS tissue, interface smoothly and intimately with host glial cells and myelinate extensively among the astrocytes of the retina. Furthermore, when implanted at a distance from a demyelinated lesion, SCPs but not Schwann cells migrate through normal CNS tissue to reach the lesion and generate new myelin. These features of SCP implants are all likely to be helpful attributes for a myelin repair cell. Since these cells also form Schwann cell myelin that is arguably likely to be resistant to MS pathology, they share some of the main advantages of Schwann cells without suffering from the disadvantages that render Schwann cells less than ideal candidates for transplantation into MS lesions.
目前,细胞移植疗法正在被积极考虑用于多种退行性疾病的治疗。在免疫介导的脱髓鞘性神经退行性疾病多发性硬化症(MS)中,只有中枢神经系统(CNS)的髓鞘会丢失,而周围神经系统(PNS)的施万细胞髓鞘保持正常。这一点,以及施万细胞能够使中枢神经系统轴突形成髓鞘这一发现,使得人们将兴趣集中于施万细胞移植以修复MS中的髓鞘。然而,在动物模型中对这些细胞进行髓鞘修复的实验应用揭示了一些与外周神经胶质细胞和中枢神经系统胶质环境不相容相关的问题。在此,我们测试了通过使用施万细胞谱系的早期阶段,即施万细胞前体(SCP),是否可以避免这些困难。为了直接比较这两种细胞类型,我们在各种实验条件下将出生后大鼠神经的施万细胞和胚胎第14天(E14)大鼠神经的SCP植入中枢神经系统。在1个月和2个月后进行检查发现,在存在裸露的中枢神经系统轴突的情况下,这两种类型的细胞都会形成髓鞘,其抗原性和超微结构类似于外周神经中施万细胞形成的髓鞘。然而,就我们研究的所有其他参数而言,这两种植入物中的细胞表现出显著不同。正如先前工作所预期的那样,施万细胞植入物存活不佳,除非细胞找到轴突进行髓鞘形成,细胞不会从植入部位显著迁移,无法与宿主少突胶质细胞和星形胶质细胞整合,并且在受到视网膜中富含星形胶质细胞的环境挑战时形成很少的髓鞘。另一方面,在植入SCP后,细胞存活良好,迁移穿过正常的中枢神经系统组织,与宿主胶质细胞顺利且紧密地相互作用,并在视网膜的星形胶质细胞之间广泛形成髓鞘。此外,当在距脱髓鞘病变一定距离处植入时,SCP而不是施万细胞会迁移穿过正常的中枢神经系统组织到达病变并产生新的髓鞘。SCP植入物的这些特征都可能是作为髓鞘修复细胞的有益属性。由于这些细胞也形成施万细胞髓鞘,而这种髓鞘可以说可能对MS病理具有抗性,它们具有施万细胞的一些主要优点,同时又不会遭受使施万细胞不太适合移植到MS病变中的那些缺点。